Exponent/Chanelle HoldCo 3 Limited
Transaction details
The proposed acquisition by Exponent Private Equity LLP through its subsidiary Herriot Pharma Bidco Limited of the entire issued share capital and thus sole control of Chanelle HoldCo 3 Limited has been cleared by the Competition and Consumer Protection Commission.
Case details
- Notification date:13 February 2024
- Publication date:13 February 2024
- Economic sector:Manufacturing - C
- Economic sub-sector:Manufacture of pharmaceuticals - C.21
- Simplified merger:Yes
- Outcome:Cleared
Documents
M/24/010 Meger AnnouncementPDF | 110 KBM/24/010 Meger Announcement PDF | 110 KB - Opens in new window
M/24/010 DeterminationPDF | 205 KBM/24/010 Determination PDF | 205 KB - Opens in new window
Parties Involved
Exponent Private Equity LLP
Exponent Private Equity LLP is an international private equity group based in the United Kingdom which makes investments in businesses in the State, the UK and across Europe.
Herriot Pharma Bidco Limited
Herriot Pharma Bidco Limited is a limited liability company. Herriot Pharma Bidco Limited is a subsidiary of Exponent Private Equity LLP.
Chanelle HoldCo 3 Limited
Chanelle HoldCo 3 Limited is a direct subsidiary of Chanelle Pharma Limited. Chanelle HoldCo 3 Limited specialises in the development, registration, manufacture, wholesale, distribution, out-license, commercialisation and supply of both human and veterinary generic pharmaceutical products.
Contacts
Éadaoin Burns eadaoinburns@ccpc.ie
